Drug intelligence / Profile preview

BO-001

Development stage: Preclinical
Lead developer: BIOPHTA
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Ophthalmic, Topical

Overview

BO-001 is a non-invasive, self-administered ophthalmic insert being developed by Biophtha for the treatment of glaucoma. It utilizes a proprietary thiomer biopolymer hydrogel platform designed to provide sustained, controlled release of an undisclosed active pharmaceutical ingredient over approximately seven days. This delivery system aims to improve patient compliance and therapeutic outcomes by reducing the frequency of administration compared to traditional daily eye drops. The candidate is currently in the IND-enabling phase of development, with clinical trials planned to begin in 2025.

Beyond the preview

Go deeper on BO-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BO-001.

Explore the full profile